{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:13:22Z","timestamp":1759778002852},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,5,29]],"date-time":"2007-05-29T00:00:00Z","timestamp":1180396800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1038\/sj.bjc.6603788","type":"journal-article","created":{"date-parts":[[2007,5,29]],"date-time":"2007-05-29T08:28:37Z","timestamp":1180427317000},"page":"1650-1655","source":"Crossref","is-referenced-by-count":23,"title":["A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer"],"prefix":"10.1038","volume":"96","author":[{"given":"M","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,29]]},"reference":[{"key":"BF6603788_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1385\/IJGC:34:2-3:107","volume":"34","author":"AW Blackstock","year":"2003","unstructured":"Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA (2003) Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34: 107\u2013116","journal-title":"Int J Gastrointest Cancer"},{"key":"BF6603788_CR2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0360-3016(01)02740-7","volume":"52","author":"CH Crane","year":"2002","unstructured":"Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52: 1293\u20131302","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF6603788_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","volume":"24","author":"CH Crane","year":"2006","unstructured":"Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA (2006) Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24: 1145\u20131151","journal-title":"J Clin Oncol"},{"key":"BF6603788_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1200\/JCO.2005.04.1749","volume":"24","author":"BG Czito","year":"2006","unstructured":"Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI (2006) Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 24: 656\u2013662","journal-title":"J Clin Oncol"},{"key":"BF6603788_CR5","first-page":"104","volume":"25","author":"J Furuse","year":"2005","unstructured":"Furuse J, Okusaka T, Funakoshi A, Boku N, Yamao K, Ohkawa A, Saito H (2005) A phase II study of S-1 in patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol (abstract) 25: 104","journal-title":"Proc Am Soc Clin Oncol (abstract)"},{"key":"BF6603788_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/jnci\/80.10.751","volume":"80","author":"Gastrointestinal Tumor Study Group","year":"1988","unstructured":"Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751\u2013755","journal-title":"J Natl Cancer Inst"},{"key":"BF6603788_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.oraloncology.2004.01.013","volume":"40","author":"K Harada","year":"2004","unstructured":"Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M (2004) Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 40: 713\u2013719","journal-title":"Oral Oncol"},{"key":"BF6603788_CR8","first-page":"2000","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5: 2000\u20132005","journal-title":"Clin Cancer Res"},{"key":"BF6603788_CR9","first-page":"1381","volume":"28","author":"Y Inuyama","year":"2001","unstructured":"Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381\u20131390","journal-title":"Gan To Kagaku Ryoho"},{"key":"BF6603788_CR10","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1516::AID-CNCR11>3.0.CO;2-0","volume":"79","author":"H Ishii","year":"1997","unstructured":"Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H (1997) Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79: 1516\u20131520","journal-title":"Cancer"},{"key":"BF6603788_CR11","first-page":"3755","volume":"26","author":"Y Ito","year":"2006","unstructured":"Ito Y, Okusaka T, Kagami Y, Ueno H, Ikeda M, Sumi M, Imai A, Fujimoto N, Ikeda H (2006) Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer. Anticancer Res 26: 3755\u20133759","journal-title":"Anticancer Res"},{"key":"BF6603788_CR12","first-page":"101","volume":"28","author":"Japan Society for Cancer Therapy","year":"1993","unstructured":"Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101\u2013130","journal-title":"J Jpn Soc Cancer Ther"},{"key":"BF6603788_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1054\/bjoc.2001.2031","volume":"85","author":"M Kawahara","year":"2001","unstructured":"Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939\u2013943","journal-title":"Br J Cancer"},{"key":"BF6603788_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0360-3016(03)00449-8","volume":"56","author":"CJ McGinn","year":"2003","unstructured":"McGinn CJ, Zalupski MM (2003) Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials. Int J Radiat Oncol Biol Phys 56: 10\u201315","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF6603788_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0140-6736(69)92326-5","volume":"2","author":"CG Moertel","year":"1969","unstructured":"Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA (1969) Combined 5-fluorourail and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2: 865\u2013867","journal-title":"Lancet"},{"key":"BF6603788_CR16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","volume":"48","author":"CG Moertel","year":"1981","unstructured":"Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas Jr HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000\u2009rads) radiation alone, moderate dose radiation (4000\u2009rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48: 1705\u20131710","journal-title":"Cancer"},{"key":"BF6603788_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/JCO.2004.03.129","volume":"22","author":"JH Muler","year":"2004","unstructured":"Muler JH, McGinn CJ, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski MM (2004) Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 22: 238\u2013243","journal-title":"J Clin Oncol"},{"key":"BF6603788_CR18","first-page":"465","volume":"16","author":"E Nakata","year":"2006","unstructured":"Nakata E, Fukushima M, Takai Y, Nemoto K, Ogawa Y, Nomiya T, Nakamura Y, Milas L, Yamada S (2006) S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1\/FU human colon cancer xenografts resistant to 5-FU. Oncol Rep 16: 465\u2013471","journal-title":"Oncol Rep"},{"key":"BF6603788_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1054\/bjoc.2000.1236","volume":"83","author":"A Ohtsu","year":"2000","unstructured":"Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma S-1. Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141\u2013145","journal-title":"Br J Cancer"},{"key":"BF6603788_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bjc.6602001","volume":"91","author":"T Okusaka","year":"2004","unstructured":"Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H (2004) Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91: 673\u2013677","journal-title":"Br J Cancer"},{"key":"BF6603788_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/01.coc.0000046300.88847.BF","volume":"27","author":"T Rich","year":"2004","unstructured":"Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small Jr W, Safran H, Wanebo HJ (2004) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27: 51\u201356","journal-title":"Am J Clin Oncol"},{"key":"BF6603788_CR22","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","volume":"34","author":"Y Sakata","year":"1998","unstructured":"Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1\u2009M tegafur\u201304\u2009M gimestat\u20131\u2009M otastat potassium) in advanced gastric cancer patients.. Eur J Cancer 34: 1715\u20131720","journal-title":"Eur J Cancer"},{"key":"BF6603788_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996a) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548\u2013557","journal-title":"Anticancer Drugs"},{"key":"BF6603788_CR24","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996b) Antitumor activity of 1\u2009M tegafur\u20130.4\u2009M 5-chloro-2,4-dihydroxypyridine\u20131\u2009M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602\u20132606","journal-title":"Cancer Res"},{"key":"BF6603788_CR25","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1200\/JCO.2000.18.19.3384","volume":"18","author":"MS Talamonti","year":"2000","unstructured":"Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson III AB (2000) Eastern cooperative oncology group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18: 3384\u20133389","journal-title":"J Clin Oncol"},{"key":"BF6603788_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000086771","volume":"68","author":"H Ueno","year":"2005","unstructured":"Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C 2005 An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68: 171\u2013178","journal-title":"Oncology"},{"key":"BF6603788_CR27","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1200\/JCO.2005.23.911","volume":"23","author":"CG Willett","year":"2005","unstructured":"Willett CG, Czito BG, Bendell JC, Ryan DP (2005) Locally advanced pancreatic cancer. J Clin Oncol 23: 4538\u20134544","journal-title":"J Clin Oncol"},{"key":"BF6603788_CR28","doi-asserted-by":"crossref","unstructured":"Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D (2006) Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006 Jul 19;3:CD002093","DOI":"10.1002\/14651858.CD002093.pub2"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603788","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:27:24Z","timestamp":1684412844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,29]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["BF6603788"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603788","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,29]]}}}